ProQR Shares Spiking 40%

Loading...
Loading...

ProQR Therapeutics NV PRQR shares rocketed higher in the pre-market session as the company announced its QR-010 Cystic Fibrosis treatment met its primary endpoint during its Phase 1b study.

Following four weeks of treatment, the study showed that QR-010 restored cystic  fibrosis transmembrane conductance regulator function in cystic fibrosis patients.

The company is presenting preliminary data from the Phase 1b study at the North American Cystic Fibrosis Conference today.

Shares of ProQr were higher by $2.40, or 38 percent, to $8.65.

Posted In: BiotechNewsMoversGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...